For decades, glaucoma has been defined and treated almost entirely through the lens of intraocular pressure. But a growing body of peer-reviewed research reveals a far more complex picture: glaucoma is increasingly understood as a multifactorial neurodegenerative disease of the retinal ganglion cells, sharing mechanistic overlap with conditions like Alzheimer's and Parkinson's. In this episode, host Maya Chandra sits down with Dr. Saikumar Gandapodi, Board-Certified Doctor of Oriental Medicine, practitioner of Ayurvedic Medicine, and Founder and Director of Netra Eye Institute.

Together they explore the mechanisms conventional care often underemphasizes — reduced ocular blood flow and Flammer Syndrome, mitochondrial dysfunction, oxidative stress, neurotrophin deprivation including BDNF, excitotoxicity, neuroinflammation, and even ferroptosis. Dr. Gandapodi explains how integrative ophthalmology and Netra Restoration Therapy approach the optic nerve as living neural tissue embedded in a whole-body biological environment, including the emerging gut-eye axis.

Grounded in landmark studies and honest about the quality of evidence, this conversation reframes traditional herbal medicine through modern network pharmacology while making clear that these approaches are adjunctive and complementary — never a replacement for proven pressure-lowering therapy. The goal is not to abandon what works, but to ask what more we can do to protect vision over a lifetime.

Welcome to the Netra Eye Institute Podcast,

where modern vision science meets the wisdom of integrative ophthalmology.

This is the Netra Eye Institute Podcast. Let's begin.

Welcome to The Integrative Eye, the podcast where cutting-edge ophthalmology

meets systems biology. I'm your host, Maya Chandra.

Today, we're tackling a condition that affects over seventy million people

worldwide, glaucoma,

but we're going beyond the number every patient hears about, eye pressure.

My guest is Dr. Saikumar Gandapoti, board-certified doctor of Oriental

medicine, a practitioner of Ayurvedic medicine, and founder and director of

Netra Eye Institute, a holistic eye care center.

Dr. Gandapoti, welcome.

Thank you, Maya. It’s a real pleasure.

Glaucoma is one of those conditions where the science has quietly moved ahead of the

clinic, and I think patients deserve to know that.

Before we dive in, I want to give listeners a framework.

You’ve built something called Netra Restoration Therapy.

In plain terms, what is it?

In short, Netra Restoration Therapy, or NRT, is a full-spectrum integrative

ophthalmology platform.

Rather than targeting one thing, it aims to support several biological pathways at

once. Ocular blood flow, neurotrophins like BDNF and NGF,

mitochondrial function, oxidative stress reduction, inflammatory balance, and

overall cellular resilience.

The logic is simple. If chronic eye disease is multifactorial, a single-target

approach may not be enough.

NRT is adjunctive and complementary.

It is not a cure, and it is not a replacement for proven care.

Let’s start with the central provocation of today’s episode.

For a century, glaucoma equaled high eye pressure.

-Why is that picture incomplete? -Because the numbers didn’t add up.

Studies like the Baltimore Eye Survey showed that a large fraction of people

with glaucoma have normal intraocular pressure,

and many with high pressure never develop damage.

That’s normal tension glaucoma.

So pressure is a major risk factor, the only one we can reliably modify,

but it isn’t the disease itself.

The disease is the progressive death of retinal ganglion cells, the neurons that

carry vision to the brain.

-That reframing matters enormously. -So if it’s fundamentally the death of

neurons,

you’re saying glaucoma is a neurodegenerative disease?

Increasingly, yes.

Researchers like Francesca Cordeiro and Leonard Levin have long argued this.

Glaucoma shares mechanistic features with Alzheimer’s and Parkinson’s,

protein aggregation, mitochondrial failure, chronic inflammation, and even

trans-synaptic degeneration that reaches the visual brain.

Once you see the optic nerve as brain tissue, the whole therapeutic conversation

changes.

You start asking about neuroprotection, not just plumbing.

Let’s get mechanistic.

One theme in the research is blood flow.

Why would circulation matter if the problem is pressure?

Because retinal ganglion cells are metabolically ravenous, and they depend on

tightly regulated perfusion.

Joseph Flammer’s work described what we now call Flammer syndrome,

a vascular dysregulation often in people with cold hands, low blood pressure, and

heightened stress reactivity. The optic nerve head suffers unstable blood flow,

endothelial dysfunction, and reperfusion injury.

That’s why some patients keep losing vision even when pressure is perfectly

controlled.

Ocular perfusion pressure, not just eye pressure, appears to matter.

That’s fascinating.

So a patient could have textbook-normal pressure and still be losing ground.

What’s happening at the cellular level to those neurons?

Several things at once. First, mitochondrial dysfunction.

Neeraj Osborn and others showed the optic nerve head is exquisitely sensitive to

energy failure. Second, oxidative stress,

an overflow of reactive oxygen species that damages membranes and DNA.

Third, excitotoxicity,

excess glutamate overstimulating NMDA receptors, which is exactly why memantine

was studied in glaucoma. And fourth, chronic neuroinflammation with activated

microglia releasing TNF alpha, IL-one beta, and IL-six.

These aren't separate diseases. They're a self-reinforcing loop.

You mentioned neurotrophins earlier.

-Where does BDNF fit into this cascade? -BDNF, brain-derived neurotrophic factor,

is essentially survival signaling for neurons.

In glaucoma, elevated pressure obstructs axonal transport at the optic nerve head,

so BDNF made in the brain can't travel back to the ganglion cell bodies.

The cells are starved of their survival signal.

Work from groups like Larry Benowitz and others has shown that restoring

neurotrophic support can promote ganglion cell survival in models.

It’s a compelling target, though I’d stress most of this is still preclinical.

Let’s talk about a newer term I’ve seen in the literature:

ferroptosis.

-What is it, and why is it relevant here? -Ferroptosis is an iron-dependent form of

cell death, driven by lipid peroxidation, described by Brent Stockwell around two

thousand twelve.

Recent studies suggest retinal ganglion cells may die partly through this pathway

after ischemic or pressure injury.

It’s exciting because it connects iron handling, oxidative stress, and cell death

into one druggable node.

But I want to be honest—this is emerging, largely animal and cell culture data.

-It’s a frontier, not established therapy. -So we have blood flow, mitochondria,

oxidative stress, excitotoxicity, inflammation, neurotrophin loss,

ferroptosis—that’s a lot of simultaneous fires. What is conventional ophthalmology

missing?

I’d say nothing it does is wrong.

Lowering pressure with drops, lasers, or surgery genuinely slows progression, and

the evidence there is excellent.

What’s underemphasized is everything downstream of pressure.

Conventional care is superb at the mechanical target and less equipped for

the biological terrain—the metabolism, the circulation, the inflammatory

environment.

Integrative ophthalmology tries to fill that gap as an adjunct, not a substitute.

You’ve hinted at whole-body factors. There’s a provocative idea in your field:

a gut–eye axis.

Can the gut really influence the optic nerve?

It’s early but genuinely intriguing.

Increased intestinal permeability—what people casually call leaky gut—can drive

systemic low-grade inflammation, elevating circulating cytokines and even

influencing microglial activation in the retina and brain.

Some researchers have explored gut microbiome differences in glaucoma and

commensal microbiota influencing T-cell responses against the optic nerve.

Gil and colleagues published intriguing work on commensal microflora and

glaucomatous neurodegeneration. Again, hypothesis-generating, not settled.

But it fits the systems biology picture.

Let’s bring in the traditional medicine dimension, because that’s core to your

practice.

When you use herbal formulas, how should a scientifically minded listener understand

-what’s actually happening? -Through network pharmacology, a single

herb may contain dozens of bioactive compounds. A classical formula? Hundreds.

Instead of one molecule hitting one target, you get many compounds nudging

many pathways gently.

Modern tools—transcriptomics, proteomics, metabolomics—let us map those effects.

So I don’t present these as folk remedies. I present them as multicomponent,

multitarget interventions that happen to match a multifactorial disease.

The framework fits the biology.

Can you give a concrete example?

An herb where we actually understand the mechanism.

Ginkgo biloba is the classic one.

In a small crossover trial published in Ophthalmology in two thousand three,

Rich and colleagues found ginkgo extract improved visual field parameters in some

normal-tension glaucoma patients.

Mechanistically, it improves ocular blood flow, scavenges free radicals, and

supports mitochondria.

Saffron and its compound crocin show antioxidant and neuroprotective signals in

models.

These aren’t magic—the effect sizes are modest, and trials are small—but the

mechanisms are real and worth studying rigorously.

You also work within traditional frameworks like TCM and Ayurveda. When you

say something like “blood stasis” or “Vata,” how do you translate that for a

modern audience?

As conceptual parallels, never exact equivalents.

In Chinese medicine, blood stasis and liver blood deficiency map loosely onto

impaired microcirculation and inadequate perfusion—very much the FLAMEA picture.

In Ayurveda, a Vata imbalance echoes dysregulation and dryness, perhaps

autonomic instability.

Majja dhatu relates to nervous tissue nourishment.

I use these as clinical lenses, then anchor decisions in measurable biology.

They’re maps, not the territory.

How does NRT actually operationalize all of this for a patient sitting in front of

-you? -It layers onto standard care.

The patient keeps their pressure-lowering treatment and their ophthalmologist.

On top, we assess perfusion, inflammation, metabolic and nutritional status,

sleep, stress, and gut health.

Then we support the terrain:

targeted botanicals, mitochondrial and antioxidant support—like citicoline, where

evidence exists—blood flow support, and lifestyle.

Citicoline, for instance, has human data from Parisi and colleagues suggesting

modest neuroprotective signals.

The philosophy is: protect the neuron while the pressure is managed.

Let's be rigorous.

When you look across this evidence base,

-how do you rate the quality honestly? -It's a spectrum.

Pressure lowering, strong randomized human trials.

Citicoline and ginkgo, some human data, small and preliminary.

Ferroptosis and gut-eye axis, mostly animal and cell studies,

hypothesis-generating.

I'm careful not to let mechanistic elegance masquerade as proven benefit.

My honest position,

promising, worth pursuing, not yet definitive.

Patients deserve that precision.

What emerging research excites you most right now?

Two things.

First, neuroprotection and even regeneration.

The work on reprogramming and neurotrophic pathways from labs like Zhigang He's

suggesting optic nerve axons might one day regrow.

Second, the convergence. The realization that glaucoma, Alzheimer's, and vascular

disease share machinery means a therapy for one may help another. That systems

view, the eye as a window into whole body neurodegeneration, is the future.

For the patient listening who has glaucoma and feels frightened, what's your closing

-message? -Take your pressure-lowering treatment

seriously. It's the foundation, and it works.

But know that you are more than your eye pressure. Your circulation, your

metabolism, your inflammation, your gut, your sleep all shape whether those

precious neurons survive. Integrative care isn't about rejecting medicine. It's

about widening the circle of what we're willing to support. That's a hopeful

message, and it's grounded in real science.

Dr. Saikumar Gandapoti, thank you for a genuinely illuminating conversation.

Thank you, Maya, and to everyone listening, protect your vision and stay

curious